2609 5th Ave     |       (206) 441-7984    |      MON-WED: 10am - 1pm & 3pm -7pm | THURS: 1pm - 7pm | FRI: Closed


Belltown Spine & Wellness has helped thousands of people over the past 25 years regain their health and vitality in Seattle.

Seattle Chiropractor - Belltown Spine & Wellness


Belltown Spine & Wellness Services

Belltown Spine & Wellness is an integrated health and wellness center that has helped thousands of people regain their health and vitality in the greater Seattle area. Services are customized and targeted for each individual's health goals.  Dr. Scott Mindel, Seattle chiropractor and owner of Belltown Spine & Wellness, created the signature 4-step program that is specifically designed to help patients recover from chronic neck and back pain conditions along with using the latest rehabilitation techniques available today.

Corrective Chiropractic Care

Belltown Spine & Wellness practices the state-of-the-art Corrective Biophysics Technique using Mirror Image exercise, adjusting and postural traction to correct the spine, and posture deviations back towards normal alignment and balance. Founder, Dr. Scott Mindel's 4-step Method has helped his patients restore overall health for over two decades in Seattle.

Massage Therapy

Belltown Spine & Wellness offers different types of massage to best suit individual client needs and preferences, including deep tissue, Swedish, and Manual Ligament Therapy, sports massage, lymphatic drainage, Healing Touch, trigger point therapy, reflexology, craniosacral, intra-oral, and pre-natal massage.

Naturopathic Medicine & Acupuncture

Holistic medicine is a form of healing that considers the body, mind, spirit, and emotions in the quest for optimal health and wellness do one can achieve optimal health by gaining proper balance in life. Naturopathic medicine, acupuncture and chiropractors target the root cause of an issue as opposed to simply reducing or managing symptoms.

Our Seattle Chiropractors & Doctor

Dr. Scott Mindel

Dr. Scott Mindel

Doctor of Chiropractic
Dr. Gion Monn


Doctor of Chiropractic
Dr. Julie Sutton

Dr. Julie Sutton

Naturopathic Doctor / Licensed Acupuncturist


Early findings from a major research initiative of the Crohn’s & Colitis Foundation of America (CCFA) suggest that specific bacteria play a central

role in Crohn’s disease and ulcerative colitis (UC), also known as inflammatory bowel diseases (IBD). The evidence raises the possibility of developing new treatments to target the gut microbiome—the "ecosystem" of microbes populating the intestines—linked to the development of IBD.

Understanding the role of the gut microbes is the focus of the CCFA Microbiome Initiative. "This research is beginning to tell us about how some 'bad' bacteria are specifically linked to IBD, IBD families, and disease flares," comments Jonathan Braun, MD, PhD, of the David Geffen School of Medicine at UCLA. "We're still just at the beginning, but this line of research opens the possibility of manipulating the immune system and the balance of good and bad bacteria to influence the course of IBD."

The CCFA Microbiome Initiative—coordinated with another major research program, the CCFA Genetics Initiative—represents an effort to understand the interrelated microbial and genetic factors involved in Crohn's disease and UC. Researchers working on the Microbiome Initiative recently announced initial results of a three-year study, providing valuable new insights into the differences in the gut bacteria related to IBD.

The results show significant differences in the intestinal bacteria of people with and without IBD. What's more, those bacterial populations change when patients with Crohn's disease or UC experience a symptomatic worsening, or "flare" of their condition. Preventing such flares is an important goal of treatment for IBD.

Highlighting the complex interplay between the microbiome and genetic factors, the study also shows that unaffected family members of patients with IBD had the "same basic profile" of gut bacteria. Research from the CCFA Microbiome Initiative has already led to new tests to determine whether an individual has a microbial population associated with IBD.

The links between gut bacteria, risk of IBD, and IBD flares raise the possibility of monitoring the microbiome and altering it to prevent or treat IBD flares. "For example, patients could receive medications to block specific enzymes, or dietary choices—possibly including probiotics—to stimulate a healthier microbiome," says Dr Braun. "However," he adds, "a great deal more research will be needed to identify the most promising treatments, and design studies to evaluate their benefits for people living with IBD."

Ultimately, the combined work of the CCFA Microbiome and Genetic Initiatives may lead to the development of individualized therapy for IBD—targeted to the individual's genetic background, gut bacteria, and individual disease course.

"Researchers working on the Microbiome and Genetics Initiatives are making discoveries with real potential to lead to new treatments that can improve the lives of patients and families affected by IBD," comments Caren A. Heller, MD, MBA, the Chief Scientific Officer of the CCFA. "We're optimistic that these lines of research will lead to a better understanding and improved clinical management of Crohn's disease and ulcerative colitis in the not-too-distant future."

Crohn's disease and ulcerative colitis are painful, medically incurable illnesses that attack the digestive system. Crohn's disease may attack anywhere along the digestive track, while ulcerative colitis inflames only the large intestine (colon). Symptoms may include abdominal pain, persistent diarrhea, rectal bleeding, fever, fatigue and weight loss. Many patients require hospitalization and surgery. These illnesses can cause severe complications, including colon cancer in patients with long-term disease. Some 1.4 million American adults and children suffer from Crohn's disease or ulcerative colitis.

Source: The Crohn's & Colitis Foundation of America, ccfa.org